Logo

Alnylam Closes Acquisition of Merck's RNAi Assets

Mar 06, 2014
Premium

Alnylam Pharmaceuticals this week announced that it has closed its previously announced acquisition of Merck's RNAi assets, including its Sirna Therapeutics subsidiary.

Merck, which acquired Sirna in 2007 for $1.1 billion, unveiled a company-wide restructuring last year that included a reduction in emphasis on platform technologies, including RNAi. In January, the company disclosed that it would sell its RNAi assets to Alnylam in exchange for $25 million in cash and $150 million in stock.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Merck
Alnylam
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.